|
1
|
Bray F, Jemal A, Grey N, Ferlay J and
Forman D: Global cancer transitions according to the Human
Development Index (2008–2030): A population-based study. Lancet
Oncol. 13:790–801. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fan L, Strasser-Weippl K, Li JJ, St Louis
J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM and Goss PE: Breast
cancer in China. Lancet Oncol. 15:e279–e289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, DeSantis C, Virgo K, Stein K,
Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al:
Cancer treatment and survivorship statistics, 2012. CA Cancer J
Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Baguley BC: Multiple drug resistance
mechanisms in cancer. Mol Biotechnol. 46:308–316. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen S, Cai J, Zhang W, Zheng X, Hu S, Lu
J, Xing J and Dong Y: Proteomic identification of differentially
expressed proteins associated with the multiple drug resistance in
methotrexate-resistant human breast cancer cells. Int J Oncol.
45:448–458. 2014.PubMed/NCBI
|
|
6
|
Borer RA, Lehner CF, Eppenberger HM and
Nigg EA: Major nucleolar proteins shuttle between nucleus and
cytoplasm. Cell. 56:379–390. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yung BY: Oncogenic role of
nucleophosmin/B23. Chang Gung Med J. 30:285–293. 2007.PubMed/NCBI
|
|
8
|
Lim MJ and Wang XW: Nucleophosmin and
human cancer. Cancer Detect Prev. 30:481–490. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Grisendi S, Mecucci C, Falini B and
Pandolfi PP: Nucleophosmin and cancer. Nat Rev Cancer. 6:493–505.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Meng Q, Lei T and Zhang M, Zhao J, Zhao XH
and Zhang M: Identification of proteins differentially expressed in
adriamycin-resistant (pumc-91/ADM) and parental (pumc-91) human
bladder cancer cell lines by proteome analysis. J Cancer Res Clin
Oncol. 139:509–519. 2013. View Article : Google Scholar
|
|
11
|
Lin M, Hu J, Liu T, Li J, Chen B and Chen
X: Knockdown of nucleophosmin by RNA interference reverses
multidrug resistance in resistant leukemic HL-60 cells.
Immunobiology. 218:1147–1154. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Swaminathan V, Kishore AH, Febitha KK and
Kundu TK: Human histone chaperone nucleophosmin enhances
acetylation-dependent chromatin transcription. Mol Cell Biol.
25:7534–7545. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Carafa V, Miceli M, Altucci L and Nebbioso
A: Histone deacetylase inhibitors: A patent review (2009–2011).
Expert Opin Ther Pat. 23:1–17. 2013. View Article : Google Scholar
|
|
14
|
Rao R, Fiskus W, Ganguly S, Kambhampati S
and Bhalla KN: HDAC inhibitors and chaperone function. Adv Cancer
Res. 116:239–262. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang F, Lu W, Zhang T, Dong J, Gao H, Li
P, Wang S and Zhang J: Development of novel ferulic acid
derivatives as potent histone deacetylase inhibitors. Bioorg Med
Chem. 21:6973–6980. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang J, Li A, Yang Y and Li X:
Identification of cyclophilin A as a potential prognostic factor
for clear-cell renal cell carcinoma by comparative proteomic
analysis. Cancer Biol Ther. 11:535–546. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang L, Chen B, Lin M, Cao Y, Chen Y, Chen
X, Liu T and Hu J: Decreased expression of nucleophosmin/B23
increases drug sensitivity of adriamycin-resistant Molt-4 leukemia
cells through mdr-1 regulation and Akt/mTOR signaling.
Immunobiology. 220:331–340. 2015. View Article : Google Scholar
|
|
18
|
Michl P and Downward J: Mechanisms of
disease: PI3K/AKT signaling in gastrointestinal cancers. Z
Gastroenterol. 43:1133–1139. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gao AM, Ke ZP, Wang JN, Yang JY, Chen SY
and Chen H: Apigenin sensitizes doxorubicin-resistant
hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via
inhibiting PI3K/Akt/Nrf2 pathway. Carcinogenesis. 34:1806–1814.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gray MJ, Mhawech-Fauceglia P, Yoo E, Yang
W, Wu E, Lee AS and Lin YG: AKT inhibition mitigates GRP78
(glucose-regulated protein) expression and contribution to
chemoresistance in endometrial cancers. Int J Cancer. 133:21–30.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xie X, Tang B, Zhou J, Gao Q and Zhang P:
Inhibition of the PI3K/Akt pathway increases the chemosensitivity
of gastric cancer to vincristine. Oncol Rep. 30:773–782.
2013.PubMed/NCBI
|
|
22
|
Saeki T, Tsuruo T, Sato W and Nishikawsa
K: Drug resistance in chemotherapy for breast cancer. Cancer
Chemother Pharmacol. 56(Suppl 1): 84–89. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pritchard AL and Hayward NK: Molecular
pathways: Mitogen-activated protein kinase pathway mutations and
drug resistance. Clin Cancer Res. 19:2301–2309. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cassinelli G, Zuco V, Gatti L, Lanzi C,
Zaffaroni N, Colombo D and Perego P: Targeting the Akt kinase to
modulate survival, invasiveness and drug resistance of cancer
cells. Curr Med Chem. 20:1923–1945. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jayashree BS, Nigam S, Pai A, Patel HK,
Reddy ND, Kumar N and Rao CM: Targets in anticancer research - A
review. Indian J Exp Biol. 53:489–507. 2015.PubMed/NCBI
|
|
26
|
Pan MH, Chiou YS, Chen LH and Ho CT:
Breast cancer chemoprevention by dietary natural phenolic
compounds: Specific epigenetic related molecular targets. Mol Nutr
Food Res. 59:21–35. 2015. View Article : Google Scholar
|
|
27
|
Di Leo A, Curigliano G, Diéras V, Malorni
L, Sotiriou C, Swanton C, Thompson A, Tutt A and Piccart M: New
approaches for improving outcomes in breast cancer in Europe.
Breast. 24:321–330. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ding A, Zhao W, Shi X, Yao R, Zhou F, Yue
L, Liu S and Qiu W: Impact of NPM, TFF3 and TACC1 on the prognosis
of patients with primary gastric cancer. PLoS One. 8:e821362013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nozawa Y, Van Belzen N, Van der Made AC,
Dinjens WN and Bosman FT: Expression of nucleophosmin/B23 in normal
and neoplastic colorectal mucosa. J Pathol. 178:48–52. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pianta A, Puppin C, Franzoni A, Fabbro D,
Di Loreto C, Bulotta S, Deganuto M, Paron I, Tell G, Puxeddu E, et
al: Nucleophosmin is overexpressed in thyroid tumors. Biochem
Biophys Res Commun. 397:499–504. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sari A, Calli A, Altinboga AA, Pehlivan
FS, Gorgel SN, Balci U, Ermete M, Dincel C and Cakalagaoglu F:
Nucleophosmin expression in renal cell carcinoma and oncocytoma.
APMIS. 120:187–194. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nicolini A, Carpi A and Tarro G:
Biomolecular markers of breast cancer. Front Biosci. 11:1818–1843.
2006. View Article : Google Scholar
|
|
33
|
Yap TA, Bjerke L, Clarke PA and Workman P:
Drugging PI3K in cancer: Refining targets and therapeutic
strategies. Curr Opin Pharmacol. 23:98–107. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hsu HH, Cheng LH, Ho TJ, Kuo WW, Lin YM,
Chen MC, Lee NH, Tsai FJ, Tsai KH and Huang CY: Apicidin-resistant
HA22T hepatocellular carcinoma cells massively promote pro-survival
capability via IGF-IR/PI3K/Akt signaling pathway activation. Tumour
Biol. 35:303–313. 2014. View Article : Google Scholar
|
|
35
|
Burris HA III: Overcoming acquired
resistance to anticancer therapy: Focus on the PI3K/AKT/mTOR
pathway. Cancer Chemother Pharmacol. 71:829–842. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Slupianek A, Nieborowska-Skorska M, Hoser
G, Morrione A, Majewski M, Xue L, Morris SW, Wasik MA and Skorski
T: Role of phosphatidylinositol 3-kinase-Akt pathway in
nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis.
Cancer Res. 61:2194–2199. 2001.PubMed/NCBI
|
|
37
|
Bai RY, Ouyang T, Miething C, Morris SW,
Peschel C and Duyster J: Nucleophosmin-anaplastic lymphoma kinase
associated with anaplastic large-cell lymphoma activates the
phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway.
Blood. 96:4319–4327. 2000.PubMed/NCBI
|
|
38
|
Eitoku M, Sato L, Senda T and Horikoshi M:
Histone chaperones: 30 years from isolation to elucidation of the
mechanisms of nucleosome assembly and disassembly. Cell Mol Life
Sci. 65:414–444. 2008. View Article : Google Scholar
|
|
39
|
Shi YK, Li ZH, Han XQ, Yi JH, Wang ZH, Hou
JL, Feng CR, Fang QH, Wang HH, Zhang PF, et al: The histone
deacetylase inhibitor suberoylanilide hydroxamic acid induces
growth inhibition and enhances taxol-induced cell death in breast
cancer. Cancer Chemother Pharmacol. 66:1131–1140. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Balch C, Naegeli K, Nam S, Ballard B,
Hyslop A, Melki C, Reilly E, Hur MW and Nephew KP: A unique histone
deacetylase inhibitor alters microRNA expression and signal
transduction in chemoresistant ovarian cancer cells. Cancer Biol
Ther. 13:681–693. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Venkannagari S, Fiskus W, Peth K, Atadja
P, Hidalgo M, Maitra A and Bhalla KN: Superior efficacy of
co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and
pan-histone deacetylase inhibitor against human pancreatic cancer.
Oncotarget. 3:1416–1427. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kang MR, Lee K, Kang JS, Lee CW, Lee KH,
Kim JH, Yang JW, Kim BG, Han G, Kang JS, et al: KBH-A42, a histone
deacetylase inhibitor, inhibits the growth of doxorubicin-resistant
leukemia cells expressing P-glycoprotein. Oncol Rep. 23:801–809.
2010.PubMed/NCBI
|
|
43
|
Edmond V, Brambilla C, Brambilla E,
Gazzeri S and Eymin B: SRSF2 is required for sodium
butyrate-mediated p21(WAF1) induction and premature senescence in
human lung carcinoma cell lines. Cell Cycle. 10:1968–1977. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bártová E, Pacherník J, Harnicarová A,
Kovarík A, Kovaríková M, Hofmanová J, Skalníková M, Kozubek M and
Kozubek S: Nuclear levels and patterns of histone H3 modification
and HP1 proteins after inhibition of histone deacetylases. J Cell
Sci. 118:5035–5046. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Del Bufalo D, Desideri M, De Luca T, Di
Martile M, Gabellini C, Monica V, Busso S, Eramo A, De Maria R,
Milella M, et al: Histone deacetylase inhibition synergistically
enhances pemetrexed cytotoxicity through induction of apoptosis and
autophagy in non-small cell lung cancer. Mol Cancer. 13:2302014.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wu Q, Cheng Z, Zhu J, Xu W, Peng X, Chen
C, Li W, Wang F, Cao L, Yi X, et al: Suberoylanilide hydroxamic
acid treatment reveals crosstalks among proteome, ubiquitylome and
acetylome in non-small cell lung cancer A549 cell line. Sci Rep.
5:95202015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Atadja PW: HDAC inhibitors and cancer
therapy. Prog Drug Res. 67:175–195. 2011.
|
